Background: Transitional cell carcinoma is the most common bladder cancer of dogs. Cisplatin combined with piroxicam provides superior response rates, but unacceptable rates of nephrotoxicity. Tavocept is a chemoprotectant that has mitigated cisplatin toxicity and decreased the required infusion/diuresis volume in clinical trials in humans.
T ransitional cell carcinoma (TCC) is the most common malignancy of the canine bladder, often diagnosed in a late stage of disease. 1 Because of location in the trigone, localized invasion, and high metastatic rates, localized treatment options are often ineffective. [1] [2] [3] [4] [5] [6] [7] [8] [9] Single-agent chemotherapy agents, including cisplatin, carboplatin, and vinblastine, have provided poor to modest remission rates (16, 0 , and 36%, respectively), and median survival times are <6 months. 4, 7, 10 The most effective chemotherapy protocol to date utilizes cisplatin and piroxicam, resulting in an overall response rate of 71%. 11, 12 In 1 study, however, 12/14 dogs experienced renal toxicity, and therefore, this combination is not used in practice. 12 Other chemotherapy protocols have reported response rates of 0-58%. [2] [3] [4] [5] [6] 8, 10, [13] [14] [15] [16] [17] Although the use of a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug (NSAID) may decrease overall nephrotoxicity associated with combination therapy, cisplatin's nephrotoxicity is not diminished and reported response rates are similar. 15 Novel therapies that decrease cisplatin nephrotoxicity and allow combination therapy are necessary to more effectively treat dogs with TCC. Cisplatin chemotherapy is technically more difficult to administer in veterinary practice than an alternative platinum agent, carboplatin, because of the requirement for a prolonged saline diuresis protocol to prevent cisplatin-induced nephrotoxicity. Carboplatin does not require lengthy diuresis and, as such, is routinely substituted for cisplatin as a treatment for osteosarcoma and other solid malignancies in dogs, but the comparative efficacy of carboplatin has been questioned. 18 Carboplatin has not been proven to be a superior drug for treatment of TCC in dogs, 3, 10, 19 and meta-analyses suggest it is inferior to cisplatin against many malignancies in humans including non-small-cell lung cancer. 20, 21 Tavocept (BNP7787; disodium 2,2 0 -dithio-bis-ethane sulfonate) a is a water-soluble disulfide form of mesna under investigation as a chemoprotectant. [22] [23] [24] Tavocept is converted to mesna in the kidneys, which then locally inactivates the toxic platinum species. 25 In preclinical studies, Tavocept protected against cisplatin nephrotoxicity in both rats and dogs, and the use of Tavocept before cisplatin in people allows a 75% decrease in fluid diuresis. [26] [27] [28] A similar decrease in fluid diuresis volume requirements would be ideal for dogs at risk of volume overload using the standard cisplatin administration protocol. Tavocept does not contain the free thiol group that could diminish the antitumor effects of cisplatin. Furthermore, Tavocept was found to potentiate the activity of cisplatin in studies in animals and in clinical trials in humans. [29] [30] [31] [32] Therefore, the objective of our study was to determine the safety and tolerability of combination Tavocept, cisplatin, and piroxicam therapy in dogs diagnosed with TCC of the bladder using a shortened diuresis protocol.
Materials and Methods
Client-owned dogs that were diagnosed with TCC of the urinary bladder by cytology or histopathology and were presented to the University of Missouri Veterinary Medical Teaching Hospital of any age, sex, or breed and >10 kg in body weight were eligible for enrollment with informed owner consent (University of Missouri ACUC protocol #6757). Dogs not eligible were those treated previously with chemotherapy, radiation therapy, or surgery (mass excision) or dogs with evidence of renal dysfunction (azotemia). Prior treatment with NSAIDs was allowed with a 14-day washout before trial initiation. The target enrollment number of dogs was 14, based on the number of dogs enrolled in a previous cisplatin/ piroxicam trial 11 after which we modeled our study protocol. Rather than subject client-owned dogs to a cisplatin/piroxicam protocol that had been shown previously to be nephrotoxic, we planned to compare treatment outcome in the current study to the historical group that did not receive Tavocept. 12 After immediate post-treatment emesis in the first 2 dogs enrolled, a protocol change was made and maropitant citrate b was administered SC (1 mg/kg) or PO (2 mg/kg) 1 hour before Tavocept infusion. Tavocept, 18.4 g/m 2 , was administered IV over 45 minutes. After 30 minutes of Tavocept administration, 20 minutes of concurrent diuresis using 0.9% saline at 18 mL/kg/h was begun. After completion of the 20-minute diuresis and 5 minutes postcompletion of the Tavocept infusion, 60 mg/m 2 of cisplatin c diluted in 0.9% saline to a total volume of 6 mL/kg was administered IV over 20 minutes. After cisplatin infusion, a second short diuresis was performed using 0.9% saline administered IV at a rate of 18 mL/kg/h for 20 minutes. This infusion protocol is summarized in Table 1 . Treatments were scheduled once every 3 weeks for a total of 4 treatments. Piroxicam d dosed at 0.3 mg/kg was administered PO once daily starting on the day of the first cisplatin treatment.
A CBC, biochemistry panel, and urinalysis were performed before the first chemotherapy treatment. Serum creatinine concentration was measured before each treatment and 1 week post-treatment. Blood urea nitrogen (BUN) concentration was measured before each treatment. An increase in BUN above normal reference range with a normal serum creatinine concentration prompted a piroxicam holiday and institution of omeprazole e (0.5-1.0 mg/kg PO q24h). If BUN returned to normal, piroxicam was reinstituted and omeprazole continued. If the BUN did not return to within reference range, the piroxicam holiday was continued and sucralfate f (0.5-1 g PO q8h) therapy was initiated in addition to omeprazole. If suspected gastrointestinal bleeding continued after reinstitution of piroxicam, firocoxib g (5 mg/kg PO q24h) was used as a second-line NSAID and deracoxib h (1-2 mg/kg PO q24h) as third-line NSAID. Complete blood counts were performed before cisplatin therapy and 1 week post-treatment. Neutrophil counts >2,500 cells/lL, platelet counts >100,000 /lL, and hematocrit ≥25% were required for cisplatin treatment. Drug toxicity was graded according to standard Veterinary Cooperative Oncology Group criteria.
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Before treatment, all dogs were staged using thoracic radiographs and abdominal computed tomography (CT). Before abdominal imaging, the urinary bladder was catheterized, emptied of urine, and then infused with 1.5 mL/kg of sterile saline to allow for consistency in repeated tumor measurement methodology. Tumor volume was calculated by means of 3-dimensional measurements using programmed imaging system software.
i Staging was repeated at days 42 and 84. Complete remission (CR) was defined as resolution of all clinical and imaging evidence of disease, partial remission (PR) was defined as >50% decrease in tumor volume with no new lesions, stable disease (SD) was defined as <50% change in tumor volume with no new lesions, and progressive disease (PD) was defined as >50% increase in tumor volume or development of new lesions. Overall response rate (ORR) was defined as CR + PR.
Study dogs were compared to a group of historical control dogs treated with the same dosages of cisplatin and piroxicam, but by standard diuresis protocol and without Tavocept. 11 The grade of renal toxicity (none, mild, moderate, severe), objective response rate (ORR), and median survival time (MST) were compared among the studies. Renal toxicity scores were compared between historical controls and study dogs using Fischer's exact test. A P value of <0.05 was considered statistically significant.
Results
Fourteen dogs with treatment-na€ ıve TCC were enrolled; 4 dogs were diagnosed histologically, whereas the remaining 10 dogs were diagnosed on the basis of cytology. Eight dogs completed the 12-week protocol, whereas 6 required protocol alteration or did not finish the 12-week protocol because of complications (2 dogs died from necropsy-confirmed acute renal failure or hepatic fibrosis), loss of follow-up (1 dog), withdrawn from study (2 dogs), or disease progression or no resolution of clinical signs (1 dog). The mean number of The shortened saline diuresis protocol was clinically well tolerated. All dogs were treated in 90 minutes (Fig 1) , with decreased total diuretic infusion volumes compared to historically administered cisplatin (Fig 2) . Without pretreatment anti-emetics, the first 2 dogs enrolled vomited after cisplatin was administered. However, after the protocol change and addition of maropitant before chemotherapy administration, no further emesis was noted during administration. Five dogs had evidence of myelosuppression, with all except 1 being mild grade I-II neutropenia or a 1-week dose delay as a consequence of insufficient neutrophil count for subsequent treatments. One dog had grade IV neutropenia and thrombocytopenia after its fourth dose of cisplatin. The dog subsequently died and necropsy disclosed fulminant pancreatitis and liver failure.
Secondary end points included ORR and MST compared to historical control dogs receiving cisplatin and piroxicam by standard protocol. 11 The ORR was 27%, with no CR, 3 PR, and 8 SD; 1 patient's imaging changes with a partial response are evaluable in Figure 3A and B. Three dogs were unevaluable because of lack of second measurement at day 42. The MST in the Tavocept group of dogs was 253 days (range, 20-983 days; Fig 4) in comparison with the MST of 246 days (range, 46-810 days) in the historical control group. Dogs in our study were only censored if they were lost to follow-up. Three early deaths were noted (dogs died or were euthanized before second measurements of their tumors could be completed; 2 of these dogs underwent necropsy). Two of these 3 dogs had serum creatinine concentration >2 mg/dL at the time of death. One dog died 20 days after starting the protocol from acute renal failure, cystic tubular degeneration, and liver fibrosis. A second died 32 days after study initiation because of interstitial nephritis, pancreatic Table 2 . Grades of nephrotoxicity were compared with historical data from Knapp et al., 11 where cisplatin was administered without Tavocept. Tavocept significantly reduced nephrotoxicity grades (P = 0.0406) in dogs receiving cisplatin and piroxicam compared to dogs not receiving the disulfide compound. Only 3/14 dogs had an increase in creatinine greater than 2.0 mg/dL in this protocol, compared to 9/14 in the historical control group. fibrosis, and hepatic fibrosis, and a third dog died 69 days after starting the protocol as a result of progressive disease and hydroureter. Rescue or continued chemotherapy after cessation of the study was variable, as it was not part of the initial study design and often occurred outside of the VHC under treatment by other specialists or primary veterinarians. For dogs that continued treatment at the VHC, 7 dogs had continued chemotherapy. The most commonly administered single agent was mitoxantrone, followed by vinblastine. The This specific patient had a partial response, with a 54% reduction in tumor volume; tumor is outlined with white arrows. In B, the urinary catheter is visible adjacent to the mass. majority of dogs continued to receive various NSAIDs intermittently until their deaths; 1 dog also received 6 fractions of palliative radiation therapy.
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Discussion
Our study shows that Tavocept allows a shortened diuresis protocol for cisplatin. This approach could be transformative for private practice, because the current standard of care for administering cisplatin to dogs requires all-day hospital admission or even overnight hospitalization. Tavocept facilitated outpatient treatment and markedly decreased the infusion fluid volume requirements for cisplatin administration. This is especially clinically relevant when treating small dogs or those at risk for volume overload. Shortening diuresis from over >6 hours to 90 minutes would dramatically increase the number of patients treatable in a day, free-up staff time, and decrease the volume of cisplatincontaining urine to which personnel and clients are potentially exposed.
Because the aforementioned comparator study 11 did not disclose all patients with azotemia, direct comparison with our study was not possible. Serum creatinine concentrations of dogs in our study appear to compare favorably to those of dogs in another study 12 that did not receive Tavocept (Table 2 ). This observation is consistent with the decrease in moderate-to-severe nephrotoxicity reported here, as compared to the prior study (21% vs. 75%). Although dogs had increased serum creatinine concentrations from baseline, only 2 dogs had concurrent isosthenuria in the face of azotemia (based on serum creatinine concentrations >1.6 mg/dL). One of these patients died within 20 days of initiation of the study. On necropsy, this dog had acute renal failure, cystic tubular degeneration, and hepatic fibrosis. The other isosthenuric and azotemic patient had stable disease after 4 doses of Tavocept/cisplatin, but developed recurrence and was treated with mitoxantrone, vinblastine, and palliative radiation therapy. The dog continued to have progressive renal disease until it was euthanized 316 days after initiation of Tavocept/cisplatin.
It is acknowledged that different methods were used to measure bladder tumors across published studies, and therefore, it is difficult to compare response rates in the various studies, especially those performed at different institutions. In our study, we attempted to be as stringent as possible in measuring the tumors by use of computed tomography imaging and software-aided analysis response measurement. Standard, repeatable volumes of sterile saline were infused before measurement, and tumor volume was calculated using 3-dimensional measurements and programmed imaging software. In oncology centers for humans, computed tomography (CT) is the imaging modality of choice for bladder cancer and has supplanted IV urography and ultrasound imaging for staging because of its superior accuracy of measurement. 34 When considering the percentage of change in tumor volume, several dogs were close to reaching a 50% reduction in tumor size. One dog had a 96% reduction in tumor volume by CT evaluation which, on ultrasound examination would likely have been considered a CR. Overall, this biologic response rate (CR, PR, and SD) was 90.9% (10/11), with only 1 evaluable dog having progressive disease. As previously stated, 3 dogs were unevaluable because of concurrent disease or not reaching repeat imaging at day 42.
After NSAID holidays, BUN often returned to within the reference range. Despite altering the NSAID used (piroxicam to deracoxib or firocoxib), most dogs continued to have increases in BUN, but without concurrent increases in serum creatinine concentration >2 mg/dL or isosthenuria. Although we did not determine that all dogs with increases in BUN but normal serum creatinine concentrations had verifiable gastrointestinal bleeding (because fecal occult blood tests were not performed on all dogs), 12/14 dogs had vomiting, diarrhea, hematemesis, hematochezia, melena, a positive fecal occult blood test result, or some combination of these. These signs repeatedly resolved with cessation of the NSAIDs.
Another study limitation is that 3 dogs were not evaluable by repeat tumor measurement using CT. Given the advanced stage of disease in many dogs before they are diagnosed and presented for treatment of bladder cancer, improvement in quality of life needs to be dramatic before clients will consent to continued therapy and anesthesia for repeated imaging. In the 2 early deaths (before day 42), it is not possible to discern if life-threatening renal disease was related to effects of the cancer, therapy, or both. Overall, the 21% occurrence rate of serum creatinine concentration >2.0 mg/dL is an improvement upon that historically reported with cisplatin/piroxicam (86%) or with singleagent cisplatin (50%), 10 but the combination of cisplatin and NSAIDs still raises concerns for risk of azotemia in dogs with bladder cancer. The severity of increases in serum creatinine concentration was mitigated by Tavocept, but alleviation of increases in BUN was not achieved. A longer infusion time, along with the administration of Tavocept, may be a more appropriate protocol for use in dogs at higher risk for renal impairment.
Based on our results, we plan to incorporate Tavocept into cisplatin protocols for other tumors, especially those that do not involve simultaneous administration of an NSAID. It also would be interesting to monitor for renal toxicity in dogs with tumor types not associated with the urinary system, because it would be expected that dogs with urinary cancers may have decreased renal function secondary to the impact of their cancer on the urinary system. Our group has treated 3 dogs with osteosarcoma with this Tavocept/cisplatin combination on a compassionate-use basis and obtained encouraging preliminary data in those dogs. j Interestingly, 1 dog developed azotemia after long-term carprofen administration for arthritis several months after finishing its Tavocept/cisplatin regimen. Diseasefree intervals in the 3 dogs were 352 days, 350 days, and 980 days; and corresponding survival times were 483, 362, and 1031 days. We believe that Tavocept could have an important role in the treatment of malignancies in dogs, with decreased severity of renal toxicity and also improvement in the feasibility of administration of cisplatin.
Conclusion
We conclude that Tavocept markedly decreases the time required for saline diuresis in dogs receiving cisplatin and decreases the severity of renal toxicity, based upon serum creatinine concentrations. A 5-hour decrease in required cisplatin infusion time is clinically relevant and can facilitate the reassessment and more routine use of cisplatin chemotherapy for a variety of cancers in dogs.
